Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + palbociclib
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Trametinib + palbociclib** is a combination drug regimen consisting of trametinib, a selective inhibitor of MEK1 and MEK2 in the RAF/MEK/ERK pathway, and palbociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). This combination has been investigated for synergistic anti-tumor effects in cancer therapies, particularly to overcome resistance mechanisms such as protective autophagy induced by palbociclib. Trametinib mitigates autophagy and enhances the anti-cancer efficacy of palbociclib. Clinical trials have evaluated this regimen in breast cancer and melanoma, and preclinical models in pancreatic cancer. Trametinib is developed and manufactured by GSK, and palbociclib is developed and manufactured by Pfizer[1][2][3][4][5][7][8][9].
- Brand names
- IbranceMekinist
- Other names
- trametinib plus palbociclibtrametinib and palbociclib
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on trametinib + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + palbociclib.